88 related articles for article (PubMed ID: 25885125)
1. Analysis of epithelial-cadherin and human epidermal growth factor receptor 2/ expression in gastric carcinoma using immunohistochemistry.
Dewan K; Madan R; Sengupta P; Bharadwaj R
Indian J Pathol Microbiol; 2015; 58(2):154-7. PubMed ID: 25885125
[TBL] [Abstract][Full Text] [Related]
2. Association of HER1 amplification with poor prognosis in well differentiated gastric carcinomas.
Kandel C; Leclair F; Bou-Hanna C; Laboisse CL; Mosnier JF
J Clin Pathol; 2014 Apr; 67(4):307-12. PubMed ID: 24218028
[TBL] [Abstract][Full Text] [Related]
3. Gastric adenocarcinoma expressing human epidermal growth factor receptor in South Asian population.
Shabbir A; Qureshi MA; Khalid AB; Mirza T; Shaikh A; Hasan SM
Saudi J Gastroenterol; 2018; 24(5):289-293. PubMed ID: 29806596
[TBL] [Abstract][Full Text] [Related]
4. Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue.
Kono K; Naganuma H; Sekikawa T; Amemiya H; Takahashi A; Iizuka H; Matsumoto Y
Tumour Biol; 2000; 21(3):139-44. PubMed ID: 10754464
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine and mucinous differentiation in signet ring cell carcinoma of the stomach: evidence for a common cell of origin in composite tumors.
Bartley AN; Rashid A; Fournier KF; Abraham SC
Hum Pathol; 2011 Oct; 42(10):1420-9. PubMed ID: 21419473
[TBL] [Abstract][Full Text] [Related]
6. Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas.
Chen HC; Chu RY; Hsu PN; Hsu PI; Lu JY; Lai KH; Tseng HH; Chou NH; Huang MS; Tseng CJ; Hsiao M
Cancer Lett; 2003 Nov; 201(1):97-106. PubMed ID: 14580691
[TBL] [Abstract][Full Text] [Related]
7. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype.
Watari J; Saitoh Y; Fujiya M; Shibata N; Tanabe H; Inaba Y; Okamoto K; Maemoto A; Ohta T; Yasuda A; Ayabe T; Ashida T; Yokota K; Obara T; Kohgo Y
J Gastroenterol; 2004; 39(2):104-12. PubMed ID: 15069616
[TBL] [Abstract][Full Text] [Related]
8. [CpG island methylation of E-cadherin gene promoter in gastric carcinoma].
Zhou YN; Xu CP; Han B; Ji R
Ai Zheng; 2005 Oct; 24(10):1220-4. PubMed ID: 16219136
[TBL] [Abstract][Full Text] [Related]
9. Her-2/neu assessment for gastric carcinoma: validation of scoring system.
Mrklic I; Bendic A; Kunac N; Bezic J; Forempoher G; Durdov MG; Karaman I; Prusac IK; Pisac VP; Vilovic K; Tomic S
Hepatogastroenterology; 2012; 59(113):300-3. PubMed ID: 22260838
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin expression as predictive marker of proximal resection line involvement for advanced carcinoma of the gastric cardia.
Polkowski WP; Skomra DG; Mielko J; Wallner GT; Szumiło J; Zinkiewicz K; Korobowicz EM; van Lanschot JJ
Eur J Surg Oncol; 2004 Dec; 30(10):1084-92. PubMed ID: 15522555
[TBL] [Abstract][Full Text] [Related]
11. Molecular characteristics of differentiated-type gastric carcinoma with distinct mucin phenotype: LI-cadherin is associated with intestinal phenotype.
Motoshita J; Nakayama H; Taniyama K; Matsusaki K; Yasui W
Pathol Int; 2006 Apr; 56(4):200-5. PubMed ID: 16634965
[TBL] [Abstract][Full Text] [Related]
12. Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population.
Howard EM; Lau SK; Lyles RH; Birdsong GG; Tadros TS; Umbreit JN; Kochhar R
Int J Clin Oncol; 2004 Jun; 9(3):154-60. PubMed ID: 15221598
[TBL] [Abstract][Full Text] [Related]
13. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients' survival.
Lazăr D; Tăban S; Ardeleanu C; Dema A; Sporea I; Cornianu M; Lazăr E; Vernic C
Rom J Morphol Embryol; 2008; 49(4):459-67. PubMed ID: 19050793
[TBL] [Abstract][Full Text] [Related]
14. Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis.
Ougolkov A; Yamashita K; Bilim V; Takahashi Y; Mai M; Minamoto T
Int J Colorectal Dis; 2003 Mar; 18(2):160-6. PubMed ID: 12548420
[TBL] [Abstract][Full Text] [Related]
15. [E-cadherin molecular expresion in the diffuse and intestinal types of gastric adenocarcinoma. A report from Lima, Peru].
Arévalo F; Monge E; Morales D
Rev Esp Enferm Dig; 2007 Jun; 99(6):325-9. PubMed ID: 17883295
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of Her-2/neu overexpression in breast carcinoma in Nigerians: a 5-year retrospective study.
Ugiagbe EE; Olu-Eddo AN; Obaseki DE
Niger J Clin Pract; 2011; 14(3):332-7. PubMed ID: 22037080
[TBL] [Abstract][Full Text] [Related]
17. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
Liu W; Zhong S; Chen J; Yu Y
J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer.
Ascaño JJ; Frierson H; Moskaluk CA; Harper JC; Roviello F; Jackson CE; El-Rifai W; Vindigni C; Tosi P; Powell SM
Mod Pathol; 2001 Oct; 14(10):942-9. PubMed ID: 11598162
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu and TOPIIa expression in gastric cancer reflect disease severity.
Liu HQ; Zhang SL; Song S
Hepatogastroenterology; 2012 Jun; 59(116):1290-3. PubMed ID: 22281973
[TBL] [Abstract][Full Text] [Related]
20. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression.
Koseki K; Takizawa T; Koike M; Ito M; Nihei Z; Sugihara K
Cancer; 2000 Aug; 89(4):724-32. PubMed ID: 10951333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
